Drug Eluting Balloon Market by Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon), Coating Technology (EnduraCoat, FreePac, Paccocath), End User - Global Forecast 2024-2030

Drug Eluting Balloon Market by Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon), Coating Technology (EnduraCoat, FreePac, Paccocath), End User - Global Forecast 2024-2030

The Drug Eluting Balloon Market size was estimated at USD 965.84 million in 2023 and expected to reach USD 1,098.31 million in 2024, at a CAGR 15.51% to reach USD 2,650.47 million by 2030.

A drug eluting balloon (DEB) is an innovative medical device designed for use in angioplasty procedures to treat narrowed or blocked arteries. This catheter-based technology incorporates a balloon at its tip, which is coated with an anti-proliferative medication. When the balloon is inflated within the affected artery, it mechanically dilates the vessel to restore blood flow and also delivers the therapeutic agent directly to the arterial walls. This local drug delivery helps prevent restenosis, the re-narrowing of the artery, by inhibiting the growth of neointimal hyperplasia, a common cause of vessel re-occlusion. DEBs provide a targeted pharmacological approach that complements the mechanical intervention, offering an alternative to traditional therapies such as bare-metal or drug-eluting stents. The growth of the drug eluting balloon market is primarily driven by the rising prevalence of cardiovascular diseases globally and the subsequent increase in demand for minimally invasive surgical procedures. However, the stringent regulatory approval processes can impede the market's progression. Additionally, high costs associated with DEB treatments may deter potential markets in developing countries. Despite challenges, technological advancements improving the efficacy and safety of DEBs, along with enhanced patient recovery times, present future market opportunities. Rising reimbursement policies favoring DEB procedures in developing nations create new avenues for market expansion.

Regional Insights

In the Americas, the market for drug-eluting balloons (DEBs) has been experiencing robust growth driven by several factors, including the rising prevalence of peripheral and coronary artery diseases and increased awareness of the benefits of DEBs over traditional therapies. The United States is a major contributor in this region owing to its advanced healthcare infrastructure, favorable reimbursement policies, and presence of significant market players. The region's growth is further supported by numerous clinical trials and research studies validating the efficacy and safety of DEB therapy. The EMEA region presents a diverse market landscape for DEBs. In Europe, the adoption of DEBs is gaining momentum, especially in Western European countries, with higher accessibility to new medical devices and a strong presence of established companies. The Middle East and Africa present untapped opportunities with gradual growth, propelled by improving healthcare infrastructure and increasing investment in the healthcare sector. The Asia-Pacific market for DEBs is showing significant growth potential, with the burgeoning population, the increasing incidence of diabetes-induced vascular diseases, and escalating healthcare expenditures. Moreover, APAC's market is being stimulated by the rising number of local manufacturers and favorable government initiatives to enhance healthcare infrastructure.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Drug Eluting Balloon Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing Geriatric Population Leading to Cardiovascular Diseases
    • Rising Prevalence of Peripheral and Coronary Artery Diseases
    • Favorable Approvals to Support the Growth of DEBs
    • Market Restraints
      • Issues Associated to Product Recalls of Drug-Eluting Balloons
      • Market Opportunities
        • New Developments in the Clinical Use of Drug-Coated Balloon Catheters
        • Advancement, Innovation, and Research in Drug-Coated Balloons
        • Market Challenges
          • Lack of Availability for Skilled and Trained Professionals
          • Market Segmentation Analysis
            • Type: Significance of coronary DEBs in enhancing deliverability and drug transfer
            • Coating Technology: Growing preferences for enduraCoat with better local drug release profile
            • End User: Higher adoption of DEBs in Cath Labs owing to ease of use and speed of the procedure
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug Eluting Balloon Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug Eluting Balloon Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Advanced NanoTherapies (ANT) Secures USD 4 Million Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)
              
              Advanced NanoTherapies Inc., an innovator in nanotechnology for vascular disease treatment, announced the successful completion of a USD 4 Million Series A funding extension from a reputable yet undisclosed strategic medical device company. This injection of funds is expected to fortify ANT's clinical development activities and expedite its trajectory toward securing U.S. IDE approval for its SirPlux Duo Drug-Coated Balloon (DCB).
              
              Translumina further Strengthens Its Technology Portfolio with Acquisition of Blue Medical Devices, Netherlands
              
              Translumina recently announced the strategic acquisition of Blue Medical Devices, a pioneer in producing state-of-the-art balloon catheters, including Drug Coated Balloons (DCB), situated in Helmond, Netherlands. With this purchase, Translumina expands its European footprint but also enhances its portfolio of coronary intervention solutions by incorporating Blue Medical's advanced DCB technologies.
              
              Surmodics Receives FDA Approval for the SurVeil Drug-Coated Balloon
              
              Surmodics, Inc. announced a significant advance with the FDA's approval of its state-of-the-art SurVeil drug-coated balloon (DCB). Specifically designed for treating peripheral artery disease, the SurVeil DCB can now be distributed in the United States for percutaneous transluminal angioplasty procedures on femoral and popliteal arteries.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug Eluting Balloon Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Drug Eluting Balloon Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, B. Braun Melsungen AG, Balton Sp. z o. o., Bayer AG, Becton, Dickinson and Company, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Cardionovum GmbH, Concept Medical, Cook Medical, Inc., Eurocor Tech GmbH, Invamed, iVascular S.L.U., Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Laborie Medical Technologies, Inc., Lepu Medical Technology, M.A. Med Alliance SA by Cordis Corporation, Medtronic PLC, SurModics, Inc., Terumo Corporation, Wellinq, and Zylox-Tonbridge Medical Technology Co., Ltd..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Drug Eluting Balloon Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Type
              • Coronary Drug Eluting Balloon
              • Peripheral Drug Eluting Balloon
              • Coating Technology
                • EnduraCoat
                • FreePac
                • Paccocath
                • TransPax
                • End User
                  • Ambulatory Surgery Centers
                  • Cath Labs
                  • Hospitals
                  • Region
                    • Americas
                      • Argentina
                      • Brazil
                      • Canada
                      • Mexico
                      • United States
                        • California
                        • Florida
                        • Illinois
                        • New York
                        • Ohio
                        • Pennsylvania
                        • Texas
                        • Asia-Pacific
                          • Australia
                          • China
                          • India
                          • Indonesia
                          • Japan
                          • Malaysia
                          • Philippines
                          • Singapore
                          • South Korea
                          • Taiwan
                          • Thailand
                          • Vietnam
                          • Europe, Middle East & Africa
                            • Denmark
                            • Egypt
                            • Finland
                            • France
                            • Germany
                            • Israel
                            • Italy
                            • Netherlands
                            • Nigeria
                            • Norway
                            • Poland
                            • Qatar
                            • Russia
                            • Saudi Arabia
                            • South Africa
                            • Spain
                            • Sweden
                            • Switzerland
                            • Turkey
                            • United Arab Emirates
                            • United Kingdom
                            
                            
                            Please Note: PDF & Excel + Online Access - 1 Year